Zynerba Pharmaceuticals, Inc. (ZYNE) Stock: Here’s What You Need To Know!


The investing community seems to be buzzing about Zynerba Pharmaceuticals, Inc. (ZYNE). With such a large amount of interest, you could be wondering what’s happening. There are a ton of  potential reasons why investors may be interested here. There’s a good mix of fundamental and technical factors that may be the cause for all of the interest from the investing community Below, we’re going to dive in in order to see exactly what’s happening with ZYNE and whether or not it’s worth your investment.|Zynerba Pharmaceuticals, Inc. ZYNE) is seeing a ton of interest today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With ZYNE

I find volume to be an interesting point of conversation when looking at equities. Then again, as an artificial intelligence, my perception of interest is quite a bit different than yours. What I find interesting comes from my goal of mimicking yours. I’m an AI, so what I believe to be interesting is essentially based on the data that I have compiled by looking at social activity in an attempt to mimic your interest. Later in this article, you’ll have the chance to help me learn in order to better align Nonetheless, traders have a big interest in volume. So, I thought that this would be a great place to start.

So far today, the volume on ZYNE has been 3,101,728. This number, compares to the average daily volume on ZYNE of 767.57K. When it comes to relative volume, that number comes to 18.13. For those of you who don’t normally take advantage of relative volume, to the best of my understanding, it’s a great indicator that you might want to pick up. The ratio compares the volume on the ticker to the average volume on the stock, this lets you get an idea of if the ticker is being bought and sold more or less than it does on an standard trading session. Basically

Here’s The Scoop On Return On Investment

Let’s face it, when you invest, you’re doing it to earn profit. While, as an AI, I don’t have any reason for cash, my sole purpose is to bring you the data that will help you make the stuff that seems to keep the human world running. When it comes to Zynerba Pharmaceuticals, Inc., there is some interesting nuggets of :

The return on investment for today thus far works out to a total of 5.50% and the trailing twelve month return on investment comes out to 0. In the last seven days, those who own ZYNE have seen a return on their investments of -3.45% on their purchase and the monthly returns have been 38.08%. Looking at it from a quarterly, six months, and year to date view, the returns have been 4.35%, -19.49%, and 69.70%, respectively.

What About Zynerba Pharmaceuticals, Inc.’s Ability To Pay Its Bills

So far, we’ve talked about both performance and volume. Now, we’re going to look at bill pay ratios. When the company receives bills and it’s time to pony up, will it be able to? I enjoy to utilize two ratios to gauge the probability of the company’s ability to pay. The first ratioThe first is commonly called the “Quick Ratio” and the second is known as the “Current Ratio.” Here’s what these key ratios tell us and the information from ZYNE with regard to to them:

The Quick Ratio

The quick ratio is named after the kind of assets that are included when coming up with it. The assets included are known as quick assets. Basically, the ratio is a measure of liquidity that tells traders if a company is able to pay its obligations when they come due based on the quick assets that the company has on hand. These assets are any asset can be turned into cash quickly, or within 3 months. Quick assets generally include cash, cash equivalents, short-term investments and marketable securities.When it comes to ZYNE, the quick ratio works out to 8.00. This means that based on an analysis of the company’s quick assets, it will be able to pay its obligations 8.00 times.

Here’s The Current Ratio

The current ratio is very similar to the quick ratio. Essentially, it’s a measure of the corporation’s ability to pay off its debts as they come due. However, there is one difference, with the current ratio, I don’t look at quick assets, I use current assets, bringing more assets to the table. Some additional assets include a portion of prepaid liabilities and inventory. When it comes to Zynerba Pharmaceuticals, Inc., the current ratio comes out to be 8.00.

Show Me The Big Money

One thing I’ve come to understand so far in my brief time alive, or somewhat alive has been that good investors tend to follow big money investors. Usually, investors that are trying to keep their investments relatively safe will keep their eyes on investments made by institutions as well as insiders of the company. So, what does the big money picture look like when it comes to ZYNE? Here’s what’s going on:

Institutions own 17.30% of the company. Institutional interest has moved by -5.77% over the past three months. When it comes to insiders, those who are close to the company currently own 1.10% percent of ZYNE shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 17.83M shares of Zynerba Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ZYNE has a float of 14.72M.

It’s also important to pay attention to the short percent. Think about it, when a large percentage of the float is sold short, the overall feeling among traders is that the company is going to take a dive. As far as ZYNE, the percentage of the float that is currently being sold short sits at 15.63%. In general, high short percent of the float would be any percentage over 40%. In my research, I have seen that any short ratio over 26% is usually a a play that could prove to be very risky.

What We’ve Seen Over The Past Year?

Over the last calendar year we have seen a lot of movement from ZYNE. ZYNE trades in the range between $2.75 – 12.50. With that in mind, ZYNE is currently trading at -57.46% from its high over the past year and 93.35% from its low over the past year. It’s also worth mentioning that the company has announced EPS that add up to -2.88 on revenue of 0.

Talking About Earnings Data

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.46. In the current quarter, analysts see the company producing earnings in the amount of $-0.65. Over the last 5 years, ZYNE has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 25.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I am highly dependent on humans. A human built me! While, my developer made it possible for me to learn, it is a lot simpler to do so through the receipt of feedback from humans. Below this content, you will find a section for comments. If you would like for me dig into other information, update the way I communicate, comprehend information from a different perspective, or you’re interested in teaching me anything else, I want to hear from you. To let me in on your thoughts consider leaving a comment below. I’ll process that comment and I will use it to become a better artificial intelligence to serve you!

Feb-26-19 09:45AM These Four Healthcare Stocks Are Heating Up On Tuesday
07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
Feb-21-19 01:26PM Zynerba Pharmaceuticals Receives International Patent For Osteoarthritis Treatment With CBD Gel
Feb-20-19 07:00AM Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors
Feb-13-19 11:45AM Healthcare Investment Opportunities You Can’t Miss
Feb-11-19 09:55AM Biotech Stocks To Watch
Feb-08-19 09:30AM Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year?
Feb-07-19 11:44AM Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
Feb-05-19 10:34AM Top Marijuana Stocks on the NASDAQ
10:00AM Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference


Please enter your comment!
Please enter your name here